Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)

P4, N=767, Completed, The University of Texas Medical Branch, Galveston | Active, not recruiting --> Completed

P=N/A, N=360, Not yet recruiting, Jiangsu Province Centers for Disease Control and Prevention

Our findings underscore the importance of tailored cervical cancer screening and HPV vaccination of SLE women at young age.

P2, N=51, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

P2, N=50, Recruiting, Universiteit Antwerpen

P2, N=50, Recruiting, Universiteit Antwerpen | Not yet recruiting --> Recruiting

P2, N=85, Recruiting, Centre Oscar Lambret | Trial completion date: Oct 2031 --> Dec 2031

P1, N=72, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting

P2, N=201, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027

P2/3, N=984, Not yet recruiting, Institut Gustave Roussy

P2, N=50, Not yet recruiting, Universiteit Antwerpen

We confirmed separate lots of the 9vHPV vaccine contained low copy numbers of L1 DNA, but found 9vHPV vaccine-generated antibody responses were not dependent on DNA sensing. This study has thus refined our understanding of potential mechanisms underlying the strong and long-lasting antibody responses to HPV vaccination.